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Objectives: The current study examined the trends in the incidence and prevalence 
of type 2 diabetes mellitus (T2DM) in the Medicare population. MethOds: A prospec-
tive population-based study was performed from January 1, 2008 through December 
31, 2013, to determine the prevalence and incidence of patients diagnosed with T2DM 
(International Classification of Disease, 9thRevision, Clinical Modification diagnosis 
codes 250.x0 and 250.x2) from the Medicare population. Patients with continuous 
enrollment in fee-for-service Medicare throughout the calendar year and at least 2 
years prior, were included for study. The age- and gender-adjusted prevalence and 
incidence (overall and specified by age group and gender) of T2DM were calculated 
using direct standardization to the U.S. population aged 65 years or older in 2010, 
using gender-specific age groups. Results: The annual adjusted overall prevalence 
of T2DM increased from 27.92% in 2008 to 32.00% in 2013, whereas the annual overall 
incidence rate decreased from 4.60% in 2008, to 2.79% in 2013. T2DM prevalence and 
incidence rates were higher among men compared to women, every year. Patients 
aged 80-84 had the highest prevalence rate in 2008 (30.40%) and 2011 (36.16%), whereas 
in 2012 (37.46%) and 2013 (38.57%), patients aged 85-89 had the highest prevalence 
rates. From 2008 to 2013, there was a steady growth in the prevalence rates among 
patients older than 75. In 2008, the highest T2DM incidence was observed in the Virgin 
Islands (9,885 per 100,000 person-years). In 2013, the highest incidence of T2DM was 
in New Jersey (6,143 per 100,000 person-years). cOnclusiOns: From 2008 to 2013, 
T2DM prevalence increased and incidence decreased. Men were more likely to be 
diagnosed with T2DM compared to women.
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Objectives: India as said to be the diabetic capital of the world. This systematic 
review aims to determine the association between socioeconomic status (SES) and 
complications associated with Type 2 Diabetes Mellitus. MethOds: Literature 
search was conducted in databases such as PubMed, EMBASE and the Cochrane 
library without any restrictions. References of the included studies were screened 
for additional studies. We included observational studies focussing on association 
between SES and T2DM patients. The quality of the studies was assessed using the 
Newcastle-Ottawa scale. Two authors independently performed the study selection, 
data extraction and the quality assessment process. A third author reviewed the 
output and adjudicated discussions in case of disagreement. Results: A total of 
440 studies were retrieved by the databases search, of which only 4 studies were 
included in the final review. One study reported that T2DM population with SES 
groups were at high risk for developing visual impairment (odds ratio [OR] 2.91; 95% 
confidence interval [CI] 1.24-6.85). Similarly, another study showed high prevalence 
of diabetes peripheral neuropathy in lower SES (48.4%) group compared to upper 
SES group (10.2%). A positive association of cataract was observed in low SES group 
compared to higher SES group (OR 1.67; 95% CI 1.10-2.54; one study). In contrast to 
these findings, one study reported no significant differences between SES groups 
in the occurrence of any form of micro-vascular complications. cOnclusiOns: 
The present review found very limited evidence regarding the association between 
socioeconomic status and diabetes complications. The available evidence suggest 
that diabetic peripheral neuropathy and eye related complications are high in low 
SES population, suggesting the need for educating patients with low SES to prevent 
long term complications in Indian T2DM patients. More observational studies are 
required to be conducted in the future in this context.
PDB20
the aSSocIatIon of waISt cIrcumference wIth GlycaemIc control In 
DIaBetIc PatIentS In an aSIan PoPulatIon
Azmi S1, Feisul MI2, Abdat A1, Goh A1, Abdul Aziz SH1
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, 
Malaysia
Objectives: The aim of the study was to explore the association of waist circumfer-
ence with glycaemic control in Malaysian patients with type 2 diabetes. MethOds: 
We utilised data of type 2 diabetes patients followed up in Malaysian public sec-
tor primary care clinics contained in the National Diabetes Registry in the year 
2012. The variable of interest was poor glycaemic control, defined as HbA1c≥ 6.5%. 
Multiple logistic regression was used to explore the association between glycae-
mic control and waist circumference, which was adjusted for age, sex, duration of 
diabetes, systolic blood pressure, total cholesterol, use of insulin and other medica-
tions. Results: A total of 98,825 patients with type 2 diabetes were included in the 
study. The mean age of patients was 59.9 years (SD: 10.9) and 38.9% were males. The 
mean duration of diabetes was 6.8 years (SD: 5.0) and 76.2% of patients had HbA1c 
≥ 6.5%. The mean waist circumference was 94.0 cm (SD: 11.8) for male and 90.7 cm 
(SD: 11.8) for female; while 78.3% of the patients had waist circumference above the 
cut-off (≥ 90 cm for men and ≥ 80 cm for women). Larger waist circumference was 
found to be significantly associated with HbA1c≥ 6.5% (adj. OR 1.009; p< 0.001; 95% 
CI: 1.007–1.011) after adjusting for confounding factors. cOnclusiOns: Analysis 
showed that glycaemic control was poorer in patients with higher waist circumfer-
ence than in patients with lower waist circumference.
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Prevalence and incidence rates of AD use were calculated for each calendar year and 
stratified by class therapy and age group. Sub-analyses by cardiovascular co-medi-
cation therapy and pharmaceutical cost analysis were performed. Results: Overall, 
the prevalence rate decreases from 22.0%-17.5% 2010-2014 (p< 0.001). Proportion of 
subjects treated with monotherapy increases over the study period (33,9%-38,6% 2010-
2014; p< 0.001). In particular, increases the proportion of users of metformin (18,2%-
23,7% 2010-2014; p< 0.001), while the proportion of users of sulfonylureas dropped 
(11,0%-7,2% 2010-2014; p< 0.001). Overall about 90% of elderly diabetic patients are 
treated with drugs for cardiovascular prevention. The largest increase during the study 
period occurred in subjects aged 65-74 years (54.8%-62.1% 2010-2014; p< 0.001). On the 
other hand the trend was downward both in the 75-84 and in ≥ 85 age groups (37.3%-
32.9% 2010-2014; 7.8%-5.0% 2010-2014 respectively). The per/patient/yearly drug costs 
was 2,349€ : 28.5% for AD therapy and 71.5% for other treatments. cOnclusiOns: 
The results confirm the negative trends observed in other population in the use of 
AD drugs among elderly diabetic patients. Specific trend in drug utilization patterns 
showed an increased attention towards treatment recommendations in older adults. 
Safety concerns in the elderly regarding polypharmacy such as presence of multi-
morbidity and hypoglycemic episodes could also have contributed to such a trend.
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Objectives: Diabetes mellitus type 2 (T2DM) is associated with an elevated risk of 
microvascular and macrovascular complications that are the leading cause of morbid-
ity and mortality in this patient population. In 2008, the Food and Drug Administration 
(FDA) has provided guidance for industry on how to demonstrate that new antidia-
betic drugs for T2DM are not associated with an unacceptable increase in cardiovas-
cular risk. Since introduction of the AMNOG in Germany in the year 2011, the Federal 
Joint Committee has consistently demanded the analysis of cardiovascular outcomes 
for new antidiabetics. The objective of this study is to analyze the cardiovascular risk 
associated with antidiabetics by a literature search. MethOds: To identify long-term 
outcomes studies, a targeted literature research was conducted in PubMed in 2015, 
using the search terms Diabetes Mellitus, Type 2/ drug therapy/ epidemiology/ cardio-
vascular. Included studies were categorized regarding study design, patient-inclusion 
criteria, pre-existing illness, treatment duration, treatment modus and cardiovascular 
outcomes. PubMed research was supplemented by additional searches in guidelines 
in German/English language. Results: 15 outcome studies were identified in T2DM: 
UKPDS, PROactive, STOP/NIDDM, ACCORD, ADVANCE, VADT, SAVOR-TIMI, EXAMINE, 
NAVIGATOR, RECORD, Look AHEAD, ORIGIN. Studies TECOS (sitagliptin) and ELIXA 
(lixisenatide) have reported results until mid of 2015 while data from EMPA-REG 
OUTCOMETM(empagliflozin) are expected in the second half of 2015. Combined or 
single cardiovascular outcomes were used as primary endpoints by 12 studies. None 
of the outcome studies in T2DM with cardiovascular condition that have reported 
results so far could demonstrate a significant risk reduction for macrovascular events 
in the primary endpoint. cOnclusiOns: Cardiovascular outcome studies of new 
antidiabetics are important to analyse safety of therapies as well as long-term condi-
tions and unmet need in T2DM. Especially the results of the ongoing studies are bound 
to fill the gap stressed by marketing-authorization and reimbursement agencies.
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Objectives: To explore demographic and clinical factors associated with choice 
of type 2 diabetes mellitus (T2DM) treatment at time of treatment intensifica-
tions. MethOds: For T2DM patients from the Netherlands (NL), Italy (IT), Spain 
(ES) (2007-2011) and United Kingdom (UK) (2008-2012) antidiabetic drug prescription 
records were obtained from electronic health-care record databases. Oral mono-
therapy was defined as first-line, oral dual therapy as second-line, > 2 oral treat-
ments or oral combined with an injectable as third-line and injectables only as 
fourth-line treatment. Treatment intensification was defined as starting a higher 
line of treatment. General characteristics, comedication, comorbidities and clinical 
parameters associated with choice of treatment were identified using multivariate 
logistic regression. Results: From NL, IT, ES and UK 48,479, 67,751, 348,572 and 
152,544 T2DM patients were included, respectively. For first-line treatment advanced 
age and renal comorbidity were associated with SU (all countries), whereas high 
BMI was inversely associated in UK and ES. For second-line treatment advanced age 
was associated with biguanide + SU (all countries) and renal comorbidity with SU + 
dipeptidyl peptidase-4 inhibitors (DPP4) in UK and NL. High BMI was associated with 
biguanide + thiazolidinedione (TZD) in UK and ES, and with biguanide + DPP4 (UK 
only). For third-line treatment advanced age and renal comorbidity were associated 
with SU + insulin in ES and UK, but high BMI was inversely associated with any 
third-line treatment containing insulin. For fourth-line treatment women were more 
likely to receive glucagon-like peptide-1 analogs than men in UK and ES. Calendar 
year and prior treatment played differing roles in treatment choices in different 
countries. cOnclusiOns: Age, BMI and renal comorbidity were the predominant 
factors associated with T2DM treatment choice across treatment intensifications 
in four EU countries. Associations identified in this explorative study are intended 
to identify questions for further research.
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